Effects of ritanserin, a selective and specific S2‐serotonergic antagonist, on portal pressure and splanchnic hemodynamics in rats with long‐term bile duct ligation

Hepatology

Volumn 18, Issue 2, 1993, Pages 389-393

  Fernández, Mercedes ^a   Pizcueta, Pilar ^a   García‐Pagán, Juan Carlos ^a   Feu, Faust ^a   Cirera, Isabel ^a   Bosch, Jaime ^a   Rodés, Joan ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RITANSERIN; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM; SPLANCHNIC BLOOD FLOW;

ANIMAL; BILE DUCTS; BLOOD PRESSURE; HEMODYNAMICS; HYPERTENSION, PORTAL; LIGATION; MALE; PORTAL SYSTEM; RATS; RATS, SPRAGUE-DAWLEY; REFERENCE VALUES; RITANSERIN; SEROTONIN ANTAGONISTS; SPLANCHNIC CIRCULATION; SUPPORT, NON-U.S. GOV'T; TIME FACTORS;

EID: 0027178986     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.1840180224     Document Type: Article

References (32)

1. Hypersensitivity of mesenteric veins to 5‐hydroxytryptamine and ketanserin‐induced reduction of portal pressure in portal hypertensive rats
2. Beneficial hemodynamic effects of ketanserin in patients with cirrhosis: possible role of serotonergic mechanisms in portal hypertension
3. Long‐term hemodynamic effects of ketanserin, a 5‐hydroxytryptamine blocker, in portal hypertensive patients
4. Combination of ketanserin and verapamil or propranolol in patients with alcoholic cirrhosis: search for an additive effect
5. ICI 169,369 selectively blocks 5‐hydroxytryptamine‐2 receptors and lowers portal pressure in portal hypertensive rats
6. Ritanserin decreases portal pressure in conscious and unrestrained cirrhotic rats
7. Serotonin blockade in conscious, unrestrained cirrhotic dogs with portal hypertension
8. Effects of ritanserin, a selective and specific S2‐serotonergic antagonist, on portal pressure and splanchnic hemodynamics in portal hypertensive rats
9. Portal‐systemic shunting influences hemodynamic abnormalities in bile duct ligated rats
10. Effect of two models of portal hypertension on splanchnic organ blood flow in the rat
11. Hemodynamic characterization of chronic bile duct‐ligated rats: effect of pentobarbital sodium
12. Hemodynamic characterization of conscious and ketamine‐anesthetized bile ductligated rats
13. Chronic bile duct ligation in the dog: hemodynamic characterization of a portal hypertensive model
14. Effect of propranolol on hepatic and systemic hemodynamics in dogs with chronic bile duct ligation
15. Quantitation of portosystemic shunting from the splenic and mesenteric beds in alcoholic liver disease
16. Splanchnic hemodynamics in cirrhotic patients with esophageal varices and gastrointestinal bleeding
17. Effects of somatostatin on splanchnic hemodynamics and plasma glucagon in portal hypertensive rats
18. Propranolol decreases portal pressure without changing portocollateral resistance in cirrhotic rats
19. Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal‐systemic shunting
20. Hyperglucagonemia and hyperkinetic circulation following porto‐caval shunt in the rat
21. Reference sample microsphere method cardiac output and blood flows in conscious rat
22. Measurement of splanchnic hemodynamics in portal‐hypertensive rats: application of gammalabeled microspheres
23. Measurement of portal systemic shunting in the rat by using gamma‐labeled microspheres
24. Pharmacology of potent and selective S2‐serotonergic antagonists
25. Propranolol compared with propranolol plus isosorbide‐5‐mononitrate for portal hypertension in cirrhosis
26. Enhancement of portal pressure reduction by the association of isosorbide‐5‐mononitrate to propranolol administration in patients with cirrhosis
27. Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension
28. Comparison of the hemodynamic responses to ketanserin and prazosin in portal hypertensive rats
29. Comparative pharmacological profile of ritanserin and ketanserin
30. Receptor binding properties in vitro and in vivo of ritanserin: a very potent long‐acting serotonin S2 antagonist
31. 5HT‐2 receptors in the rat portal vein
32. Effects of serotonin on the microcirculation of the normal perfused rat liver [Abstract]